| Overview |
| bsm-70350M |
| ATM (C-terminal region) Antibody |
| WB, FCM, IP, ICC |
| This antibody detects a 370 kDa* protein corresponding to the molecular mass of ATM on SDS-PAGE immunoblots of human A431 and Jurkat cells. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Clone M361 was generated from a recombinant sequence corresponding to amino acids in the C-terminal region of human ATM. |
| Monoclonal |
| M361 |
| IgG2b |
| Purified by Protein A. |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| Q13315 |
| ataxia telangiectasia mutated, AT1 ATDC TEL1 TELO1 |
| Ataxia telangiectasia mutated kinase (ATM) is a serine/threonine kinase that regulates cell cycle checkpoints and DNA repair. Mutations of ATM cause a spectrum of defects ranging from neurodegeneration to cancer predisposition. Activation of ATM after DNA damage involves Cdk5 mediated phosphorylation of Ser-794 followed by autophosphorylation at Ser-1891. Active ATM kinase regulates a number of proteins involved in cell cycle checkpoint control, apoptosis and DNA repair. The Cdk5–ATM pathway regulates phosphorylation and function of the ATM targets p53 and H2AX in postmitotic neurons. Other known substrates of ATM include Chk2, Chk1, CtIP, 4E-BP1, BRCA1, RPA3, SMC1, FANCD2, Rad17, Artemis, Nbs1, and the I-2 regulatory subunit of PP1. Thus, activation of Cdk5 by DNA damage may be an important initiator of ATM-dependent regulation of cell cycle checkpoints. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IP |
1-2ug |
| ICC |
1:100-500 |
Powered by Bioz